8T8Q

Identification of GDC-1971 (RLY-1971), a SHP2 inhibitor designed for the treatment of solid tumors


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.27 Å
  • R-Value Free: 0.249 
  • R-Value Work: 0.192 
  • R-Value Observed: 0.195 

Starting Model: experimental
View more details

wwPDB Validation   3D Report Full Report

Currently 8T8Q does not have a validation slider image.


This is version 1.1 of the entry. See complete history


Literature

Identification of GDC-1971 (RLY-1971), a SHP2 Inhibitor Designed for the Treatment of Solid Tumors.

Taylor, A.M.Williams, B.R.Giordanetto, F.Kelley, E.H.Lescarbeau, A.Shortsleeves, K.Tang, Y.Walters, W.P.Arrazate, A.Bowman, C.Brophy, E.Chan, E.W.Deshmukh, G.Greisman, J.B.Hunsaker, T.L.Kipp, D.R.Saenz Lopez-Larrocha, P.Maddalo, D.Martin, I.J.Maragakis, P.Merchant, M.Murcko, M.Nisonoff, H.Nguyen, V.Nguyen, V.Orozco, O.Owen, C.Pierce, L.Schmidt, M.Shaw, D.E.Smith, S.Therrien, E.Tran, J.C.Watters, J.Waters, N.J.Wilbur, J.Willmore, L.

(2023) J Med Chem 66: 13384-13399

  • DOI: https://doi.org/10.1021/acs.jmedchem.3c00483
  • Primary Citation of Related Structures:  
    8T6D, 8T6G, 8T7Q, 8T8Q

  • PubMed Abstract: 

    Protein tyrosine phosphatase SHP2 mediates RAS-driven MAPK signaling and has emerged in recent years as a target of interest in oncology, both for treating with a single agent and in combination with a KRAS inhibitor. We were drawn to the pharmacological potential of SHP2 inhibition, especially following the initial observation that drug-like compounds could bind an allosteric site and enforce a closed, inactive state of the enzyme. Here, we describe the identification and characterization of GDC-1971 (formerly RLY-1971), a SHP2 inhibitor currently in clinical trials in combination with KRAS G12C inhibitor divarasib (GDC-6036) for the treatment of solid tumors driven by a KRAS G12C mutation.


  • Organizational Affiliation

    Relay Therapeutics, Inc., 399 Binney St., Cambridge,, Massachusetts 02139, United States.


Macromolecules
Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChains Sequence LengthOrganismDetailsImage
Tyrosine-protein phosphatase non-receptor type 11
A, B
526Homo sapiensMutation(s): 0 
Gene Names: PTPN11PTP2CSHPTP2
EC: 3.1.3.48
UniProt & NIH Common Fund Data Resources
Find proteins for Q06124 (Homo sapiens)
Go to UniProtKB:  Q06124
PHAROS:  Q06124
GTEx:  ENSG00000179295 
Sequence Annotations
Expand
  • Reference Sequence
Small Molecules
Ligands 1 Unique
IDChains Name / Formula / InChI Key2D Diagram3D Interactions
ZJX (Subject of Investigation/LOI)
Query on ZJX

Download Ideal Coordinates CCD File 
C [auth A],
D [auth B]
1-[(3P)-3-(3-chloro-2-fluorophenyl)-1H-pyrazolo[3,4-b]pyrazin-6-yl]-4-methylpiperidin-4-amine
C17 H18 Cl F N6
QROQTLNVCIGXBV-UHFFFAOYSA-N
Binding Affinity Annotations 
IDSourceBinding Affinity
ZJX BindingDB:  8T8Q IC50: min: 213, max: 1.00e+4 (nM) from 2 assay(s)
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.27 Å
  • R-Value Free: 0.249 
  • R-Value Work: 0.192 
  • R-Value Observed: 0.195 
  • Space Group: P 1 21 1
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 46.093α = 90
b = 211.492β = 96.37
c = 55.853γ = 90
Software Package:
Software NamePurpose
PHENIXrefinement
XDSdata reduction
Aimlessdata scaling
PHENIXphasing

Structure Validation

View Full Validation Report

Currently 8T8Q does not have a validation slider image.



Entry History & Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
Other private--

Revision History  (Full details and data files)

  • Version 1.0: 2023-10-11
    Type: Initial release
  • Version 1.1: 2023-10-25
    Changes: Database references